MicroRNA-218 regulates the chemo-sensitivity of cervical cancer cells through targeting survivin

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cervical cancer is a leading cause of death in women globally, with chemo-resistance hindering effective treatment.
• The mechanisms underlying chemo-resistance in cervical cancer remain poorly understood.
• MicroRNAs are implicated in cancer chemo-resistance, prompting investigation into their specific roles.

Purpose of the Study:

• To investigate the role of microRNA-218 in chemo-resistance within cervical cancer cells.
• To determine if microRNA-218 influences sensitivity to cisplatin, a common chemotherapy drug.
• To identify potential molecular targets of microRNA-218 involved in chemo-resistance.

Main Methods:

• Real-time PCR to quantify microRNA-218 levels in cisplatin-resistant and sensitive cell lines.
• CCK-8 assays to assess the impact of microRNA-218 modulation on cisplatin sensitivity.
• Dual-luciferase reporter assays to validate survivin as a direct target of microRNA-218.
• Western blotting and PCR to analyze survivin and apoptosis-related protein expression.
• Cell apoptosis assays to evaluate the effect of microRNA-218 on programmed cell death.

Main Results:

• MicroRNA-218 was significantly downregulated in cisplatin-resistant cervical cancer cells (HeLa/DDP, SiHa/DDP).
• Upregulating microRNA-218 increased cisplatin sensitivity, while downregulation decreased it.
• Survivin was identified as a direct target of microRNA-218, with its expression inversely correlated to microRNA-218 levels.
• MicroRNA-218 induction promoted cervical cancer cell apoptosis.

Conclusions:

• MicroRNA-218 plays a crucial role in enhancing cisplatin sensitivity in cervical cancer.
• The mechanism involves the regulation of survivin expression, cell growth, and apoptosis.
• MicroRNA-218 represents a potential therapeutic target for improving cervical cancer treatment outcomes.